We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs
Read MoreHide Full Article
Key Takeaways
EW reports Q4 adjusted EPS of 58 cents, missing estimates, while revenues rose 13.3% to $1.57B.
EW's TAVR sales rose 12% to $1.16B, and TMTT jumped 48.3% on strong SAPIEN, PASCAL and EVOQUE adoption.
EW guides 2026 sales growth of 8%-10% and EPS of $2.90-$3.05, expressing confidence despite margin pressure.
Edwards Lifesciences Corporation (EW - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 58 cents, which fell short of the Zacks Consensus Estimate by 5.89%. The figure decreased 1.7% on a year-over-year basis.
One-time adjustments primarily include certain litigation expenses and restructuring expenses. GAAP EPS from continuing operations was 11 cents compared to 58 cents in the year-ago period.
Full-year adjusted EPS was $2.56, reflecting a 5.3% increase from the 2024 figure. The figure missed the Zacks Consensus Estimate by 1.2%.
Edwards’ Revenues
Sales totaled $1.57 billion, up 13.3% year over year. The metric surpassed the Zacks Consensus Estimate by 1.99%.
Full-year 2025 revenues came to $6.07 billion, up 11.5% year over year and also beat the Zacks Consensus Estimate by 0.7%.
Following the earnings announcement, EW stock rose 1.3% in the aftermarket trading yesterday.
EW’s Q4 Sales by Segments
Transcatheter Aortic Valve Replacement (“TAVR”)
Global sales in the product group amounted to $1.16 billion, up 12% year over year or 10.6% at constant currency (CER). The performance reflected clinicians’ heightened focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis.
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise
Transcatheter Mitral and Tricuspid Therapies (“TMTT”)
Sales totaled $155.7 million, up 48.3% from the prior-year figure on a reported basis. This compares with our model’s projection of $134.1 million. The global adoption of PASCAL and EVOQUE contributed to the overall growth.
Surgical Structural Heart
Global Surgical sales from continuing operations came in at $253.6 million, up 3.8% year over year. While growth was impacted by year-end distributor inventory adjustments in one country, the underlying fundamentals continued to remain strong.
Edwards’ Q4 Margin Performance
The gross profit was $1.22 billion, up 12.2% year over year. The gross margin contracted 77 basis points (bps) to 78.2% due to a 17.4% increase in the cost of sales.
SG&A expenses rose 22.6% year over year to $602.9 million. R&D expenditures amounted to $267.7 million, down 1.3% year over year.
The operating income increased 7.7% year over year to $356 million. The operating margin contracted 118 bps to 22.7%.
EW’s Cash Position
The company exited the fourth quarter with cash and cash equivalents of $3.00 billion, consistent with the year-end 2024 levels. Total debt was roughly $600 million, also in line with the 2024 figure.
Edwards’ 2026 Guidance
For 2026, the company has guided sales growth rate between 8% and 10%. The Zacks Consensus Estimate for sales is pegged at $6.61 billion, suggesting a 9.6% increase from the 2025 level.
Adjusted EPS is projected within the $2.90-$3.05 range. The Zacks Consensus Estimate is pegged at $2.88.
For the first quarter of 2026, EW projects total sales in the band of $1.55-$1.63 billion and adjusted EPS in the 70-76 cent range. The Zacks Consensus Estimate for first-quarter sales and EPS is pinned at $1.57 billion and 68 cents, respectively.
Our Take
Edwards Lifesciences closed the fourth quarter of 2025 with an earnings miss, while revenues surpassed estimates. Within TAVR, the company saw intentional and urgent treatment of severe aortic stenosis patients, fueled by a large and growing body of evidence on the SAPIEN platform and the increased adoption of SAPIEN 3 Ultra RESILIA. Surgical performance continues to benefit from the ongoing adoption of RESILIA therapies that offer extended durability of Edwards’ therapies, including INSPIRIS, KONECT and MITRIS. Supported by the strong quarterly performance and multiple catalysts, management expressed increased confidence in its 2026 outlook.
Both gross and operating margins contracted in the quarter, which is discouraging.
EW’s Zacks Rank & Key Picks
Edwards Lifesciences currently has a Zacks Rank #3 (Hold).
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 13.24%.
Envista,sporting a Zacks Rank #1 at present, posted a fourth-quarter 2025 adjusted EPS of 38 cents, exceeding the Zacks Consensus Estimate by 18.23%. Revenues of $750.6 million topped the Zacks Consensus Estimate by 411.16%.
NVST has an earnings yield of 4.7% compared with the industry’s 2.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.4%.
Align Technology,carrying a Zacks Rank #2 (Buy) at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs
Key Takeaways
Edwards Lifesciences Corporation (EW - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 58 cents, which fell short of the Zacks Consensus Estimate by 5.89%. The figure decreased 1.7% on a year-over-year basis.
One-time adjustments primarily include certain litigation expenses and restructuring expenses. GAAP EPS from continuing operations was 11 cents compared to 58 cents in the year-ago period.
Full-year adjusted EPS was $2.56, reflecting a 5.3% increase from the 2024 figure. The figure missed the Zacks Consensus Estimate by 1.2%.
Edwards’ Revenues
Sales totaled $1.57 billion, up 13.3% year over year. The metric surpassed the Zacks Consensus Estimate by 1.99%.
Full-year 2025 revenues came to $6.07 billion, up 11.5% year over year and also beat the Zacks Consensus Estimate by 0.7%.
Following the earnings announcement, EW stock rose 1.3% in the aftermarket trading yesterday.
EW’s Q4 Sales by Segments
Transcatheter Aortic Valve Replacement (“TAVR”)
Global sales in the product group amounted to $1.16 billion, up 12% year over year or 10.6% at constant currency (CER). The performance reflected clinicians’ heightened focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis.
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise
Edwards Lifesciences Corporation price-consensus-eps-surprise-chart | Edwards Lifesciences Corporation Quote
Transcatheter Mitral and Tricuspid Therapies (“TMTT”)
Sales totaled $155.7 million, up 48.3% from the prior-year figure on a reported basis. This compares with our model’s projection of $134.1 million. The global adoption of PASCAL and EVOQUE contributed to the overall growth.
Surgical Structural Heart
Global Surgical sales from continuing operations came in at $253.6 million, up 3.8% year over year. While growth was impacted by year-end distributor inventory adjustments in one country, the underlying fundamentals continued to remain strong.
Edwards’ Q4 Margin Performance
The gross profit was $1.22 billion, up 12.2% year over year. The gross margin contracted 77 basis points (bps) to 78.2% due to a 17.4% increase in the cost of sales.
SG&A expenses rose 22.6% year over year to $602.9 million. R&D expenditures amounted to $267.7 million, down 1.3% year over year.
The operating income increased 7.7% year over year to $356 million. The operating margin contracted 118 bps to 22.7%.
EW’s Cash Position
The company exited the fourth quarter with cash and cash equivalents of $3.00 billion, consistent with the year-end 2024 levels. Total debt was roughly $600 million, also in line with the 2024 figure.
Edwards’ 2026 Guidance
For 2026, the company has guided sales growth rate between 8% and 10%. The Zacks Consensus Estimate for sales is pegged at $6.61 billion, suggesting a 9.6% increase from the 2025 level.
Adjusted EPS is projected within the $2.90-$3.05 range. The Zacks Consensus Estimate is pegged at $2.88.
For the first quarter of 2026, EW projects total sales in the band of $1.55-$1.63 billion and adjusted EPS in the 70-76 cent range. The Zacks Consensus Estimate for first-quarter sales and EPS is pinned at $1.57 billion and 68 cents, respectively.
Our Take
Edwards Lifesciences closed the fourth quarter of 2025 with an earnings miss, while revenues surpassed estimates. Within TAVR, the company saw intentional and urgent treatment of severe aortic stenosis patients, fueled by a large and growing body of evidence on the SAPIEN platform and the increased adoption of SAPIEN 3 Ultra RESILIA. Surgical performance continues to benefit from the ongoing adoption of RESILIA therapies that offer extended durability of Edwards’ therapies, including INSPIRIS, KONECT and MITRIS. Supported by the strong quarterly performance and multiple catalysts, management expressed increased confidence in its 2026 outlook.
Both gross and operating margins contracted in the quarter, which is discouraging.
EW’s Zacks Rank & Key Picks
Edwards Lifesciences currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Envista (NVST - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 13.24%.
Envista,sporting a Zacks Rank #1 at present, posted a fourth-quarter 2025 adjusted EPS of 38 cents, exceeding the Zacks Consensus Estimate by 18.23%. Revenues of $750.6 million topped the Zacks Consensus Estimate by 411.16%.
NVST has an earnings yield of 4.7% compared with the industry’s 2.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.4%.
Align Technology,carrying a Zacks Rank #2 (Buy) at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.